FLT3 gene overexpression and its clinical significance in acute myeloid leukemia with AML1/ETO fusion gene positive.
10.7534/j.issn.1009-2137.2014.05.002
- Author:
Hui-Min XIE
1
;
Li GAO
2
;
Nan WANG
1
;
Yuan-Yuan XU
1
;
Jin-Long SHI
3
;
Li YU
4
;
Li-Li WANG
5
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Hematology, China-Japan Friendship Hospital, Beijing 100029, China.
3. Medical Engineering Support Center, Chinese PLA General Hospital, Beijing 100853, China.
4. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China. E-mail: chunhuiliyu@yahoo.com.
5. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China. E-mail: daughter126@126.com.
- Publication Type:Journal Article
- MeSH:
Core Binding Factor Alpha 2 Subunit;
genetics;
Gene Expression Regulation, Neoplastic;
Humans;
Leukemia, Myeloid, Acute;
genetics;
Oncogene Proteins, Fusion;
genetics;
Prognosis;
RUNX1 Translocation Partner 1 Protein;
fms-Like Tyrosine Kinase 3;
genetics
- From:
Journal of Experimental Hematology
2014;22(5):1199-1205
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the expression levels of FLT3 gene in AML-M2 patients carrying AML1/ETO fusion gene, and analyze its relation with clinical and laboratorial features and prognosis. RQ-PCR method was used to detect the expression level of FLT3 in bone marrow of 21 AML-M2 patients with AML1/ETO(+). The correlation of the expression level of FLT3 with clinical features, other laboratorial examinations and disease prognosis were analyzed. The results showed that gene expression level of FLT3 (FLT3 gene/ reference gene) in patients at initial diagnosis were 1.65%-261.5%. The expression level of FLT3 over 35% was defined as high expression group (12 cases) , while the expression level below 35% was defined as low expression group (9 cases) . The proportion of patients with extramedullary infiltration in high expression group was higher than that in low expression group (25% vs 0%, P = 0.2286). The proportion of patients at initial diagnosis with white blood cell count > 10×10(9)/L in high expression group was higher than that in low expression group (66.67% vs 22.22%), but there was no statistical significance (P = 0.0805). No significant difference was observed at the age (P = 0.1369) and the rate of bone marrow blasts (P = 0.6923) between the above mentioned two groups. The differences in complete remission rate (66.67% vs 88.89%, P = 0.3383), the relapse rate (66.67% vs 22.22%,P = 0.0805) and the mortality rate (50% vs 22.22%, P = 0.3666) between the two group were not significant, but there was a clear trend that the low expression group has a higher CR rate and a lower relapse rate and mortality rate. It is concluded that FLT3 gene high expression in AML-M2 patients with AML1/ETO(+) have a higher rate of relapse and hence poor prognosis. Therefore, detection of FLT3 expression level in routine clinical practice is important for patient's risk stratification, prognostic evaluation and effective treatment selection.
